Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DAPK1
REST API REST API
Homo sapiens
DAPK1 is differentially expressed in 336 experiments: 138 organism parts: placenta, cerebellum, ... (136 more);, 195 disease states: normal, chronic myelogenous leukemia, ... (193 more);, 116 cell types 507 cell lines 41 compound treatments and 78 other conditions.
Synonyms DAPK
Orthologs MEK1 (Saccharomyces cerevisiae)   DAPK1 (Gallus gallus)   DAPK1 (Danio rerio)   DAPK1 (Bos taurus)   Dapk1 (Mus musculus)   Dapk1 (Rattus norvegicus)   dapk1 (Xenopus laevis)   DAPK1 (Canis familiaris)   (Compare orthologs)
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom, Prot_kinase_cat_dom, RIO-like_kinase, Death, LipoPS_kinase, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene Ontology Term protein binding, apoptosis, phosphotransferase activity, alcohol group as acceptor, cytoplasm, membrane, protein tyrosine kinase activity, anti-apoptosis, positive regulation of apoptosis, calmodulin binding, ATP binding, induction of apoptosis, actin cytoskeleton, transferase activity, transferring phosphorus-containing groups, nucleotide binding, protein serine/threonine kinase activity, catalytic activity, signal transduction, lipopolysaccharide biosynthetic process, protein kinase activity, intracellular protein kinase cascade, regulation of apoptosis, induction of apoptosis by extracellular signals, protein phosphorylation
UniProt Accession B7ZLE7, P53355, Q5T8F1, F8WCQ3
Search EB-eye ENSG00000196730
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
PC3
3
E-GEOD-14464, E-GEOD-5258, E-MEXP-2034
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
501 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-21909, ... (55 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
3
E-AFMX-5, E-MTAB-24, E-MTAB-25, E-TABM-145
CD8+ T cell
1
3
E-AFMX-5, E-GEOD-19069, E-MTAB-25, E-TABM-145
dendritic cell
2
E-GEOD-3982, E-GEOD-360
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
110 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-GEOD-1577, E-TABM-15, ... (60 experiments)

Factor Value U/D Experiments
Burkitt's lymphoma
3
E-MTAB-37, E-GEOD-1880, E-GEOD-96
lung adenocarcinoma
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-MEXP-1327
myeloma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
lymphoma
2
E-MTAB-37, E-MTAB-62
189 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
hydrogen peroxide
1
E-GEOD-5339
glutamine
1
E-MEXP-941
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
1
E-GEOD-6932
dasatinib
1
E-MEXP-1561
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-MEXP-1838, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, E-GEOD-10315, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (42 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-7114, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-8167, E-GEOD-6532

Processing time: 0.359 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM